ducovest

XVIPF:OTO-Xvivo Perfusion Ab Ord (USD)

COMMON STOCK | Medical Devices | OTC Pink

Last Closing

USD 27.7

Change

0.00 (0.00)%

Market Cap

USD 0.22B

Volume

100.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Xvivo Perfusion AB is a medical technology company focused on developing optimized solutions for organ, tissue and cell preservation in connection with transplantation.

Company Website : http://www.xvivoperfusion.com

Currency: USD

Country : USA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-18 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
SMMNY Siemens Healthineers AG ADR

N/A

 USD 55.86B
SEMHF Siemens Healthineers AG

N/A

 USD 54.79B
RYLPF Koninklijke Philips N.V

N/A

 USD 22.19B
SONVF Sonova Holding AG

N/A

 USD 16.41B
OCPNF Olympus Corporation

N/A

 USD 14.51B
SNNUF Smith & Nephew plc

N/A

 USD 12.54B
SSMXF Sysmex Corporation

N/A

 USD 11.97B
WILLF Demant A/S

N/A

 USD 6.94B
GNGBF Getinge AB

N/A

 USD 5.41B
AMBBY Ambu A/S

N/A

 USD 4.72B

ETFs Containing XVIPF

RUBY-U:CA RBC U.S. Banks Yield Inde.. 6.76 % 0.00 %

N/A

 N/A
HUBL-U:CA Harvest US Bank Leaders I.. 6.69 % 0.00 %

N/A

 N/A
IAT iShares U.S. Regional Ban.. 3.99 % 0.42 %

N/A

 N/A
KRE SPDR® S&P Regional Banki.. 2.92 % 0.35 %

N/A

 N/A
FBU:CA 2.78 % 0.84 %

N/A

 N/A
KRS 2.30 % 0.95 %

N/A

 N/A
KRU 2.30 % 0.95 %

N/A

 N/A
MVIN 2.28 % 0.55 %

N/A

 N/A
DPST Direxion Daily Regional B.. 2.03 % 1.02 %

N/A

 USD 0.54B
BNKS:LSE iShares S&P U.S. Banks ET.. 0.00 % 0.00 %

N/A

 N/A
EXX5:F iShares Dow Jones U.S. Se.. 0.00 % 0.00 %

N/A

 N/A
IUS2:F iShares S&P U.S. Banks UC.. 0.00 % 0.00 %

N/A

 N/A
IUS2:XETRA iShares S&P U.S. Banks UC.. 0.00 % 0.00 %

N/A

 N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -32.60% 25% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -32.60% 25% F 15% F
Trailing 12 Months  
Capital Gain -6.13% 67% D+ 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.13% 67% D+ 48% F
Trailing 5 Years  
Capital Gain 175.51% 92% A 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 175.51% 92% A 85% B
Average Annual (5 Year Horizon)  
Capital Gain 34.20% 78% C+ 75% C
Dividend Return 34.20% 78% C+ 73% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 74.18% 44% F 39% F
Risk Adjusted Return 46.10% 93% A 82% B
Market Capitalization 0.22B 79% B- 72% C

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.